Total U.S. permanent implant procedures declined 7% year over year, while U.S. trial procedures decreased 14.2% year over year. During the fourth quarter of 2024, Nevro made significant ...

March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE ... decreased by 7.0% compared with the fourth quarter of 2023, and U.S. trial procedures decreased approximately 14.2% compared with the fourth ...

Nevro Corp. (NYSE:NVRO – Get Free Report ... shares of the medical equipment provider’s stock valued at $816,000 after purchasing an additional 62,568 shares during the last quarter.

Management uses certain non-GAAP financial measures, most specifically adjusted EBITDA, as a supplement to GAAP financial measures to further evaluate the Company's operating performance period ...

Analysts at StockNews.com started coverage on shares of Nevro (NYSE:NVRO – Get Free Report ... provider’s stock valued at $5,590,000 after buying an additional 566,462 shares during the ...

New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an ...

REDWOOD CITY, Calif. (AP) — REDWOOD CITY, Calif. (AP) — Nevro Corp. (NVRO) on Tuesday reported a loss of $53.1 million in its fourth quarter. The Redwood City, California-based company said it ...

March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE ... decreased by 7.0% compared with the fourth quarter of 2023, and U.S. trial procedures decreased approximately 14.2% compared with the fourth ...